Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of revenue | 18,708 | 16,979 |
| Research and development | 23,623 | 24,203 |
| Sales and marketing | 26,346 | 23,047 |
| General and administrative | 20,984 | 17,399 |
| Amortization of intangible assets | 419 | 419 |
| Total operating expenses | 90,080 | 82,047 |
| Loss from operations | (19,206) | (29,604) |
| Interest and other income, net | 2,080 | 2,679 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's G&A?
- Adaptive Biotechnologies (ADPT) reported G&A of $20.98M in Q1 2026.
- How has Adaptive Biotechnologies's G&A changed year-over-year?
- Adaptive Biotechnologies's G&A increased by 20.6% year-over-year, from $17.4M to $20.98M.
- What is the long-term trend for Adaptive Biotechnologies's G&A?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's G&A has grown at a -0.6% compound annual growth rate (CAGR), from $74.5M to $72.7M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Adaptive Biotechnologies's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude